Trial results

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449 on ClinicalTrials.gov · last registry update 2026-01-20

Closed to new participants; the 400 already enrolled are still being followed. Due to report 28 August 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Relative change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

400

Started

2025-02-10

Primary completion

2028-08-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.